Bone specific binding sites for 1,25(OH)2D3 in magnesium deficiency

Area of Science:

• Endocrinology
• Bone Biology
• Mineral Metabolism

Background:

• Hypoparathyroidism and magnesium deficiency can alter vitamin D treatment responses.
• Magnesium deficiency is linked to reduced 1,25-dihydroxyvitamin D3-induced bone resorption in vitro.
• These observations suggest impaired vitamin D action in bone during magnesium deficiency.

Purpose of the Study:

• To investigate the effect of magnesium deficiency on vitamin D receptors in bone.
• To determine if magnesium deficiency alters the number or affinity of 1,25-dihydroxyvitamin D3 binding sites in bone cells.

Main Methods:

• Utilized a competitive binding assay using 1,25-dihydroxyvitamin D3 and radiolabeled 3H-1,25-dihydroxyvitamin D3.
• Assayed hormone binding sites in rat calvaria homogenates.
• Compared calvaria incubated in magnesium-deficient versus magnesium-replete media.

Main Results:

• A significant decrease in the number of specific 1,25-dihydroxyvitamin D3 binding sites was observed in magnesium-deficient bone.
• No alterations in hormone-receptor affinity were detected.
• The reduction in binding sites suggests impaired vitamin D signaling.

Conclusions:

• Magnesium deficiency leads to a reduced number of vitamin D receptors in bone cells.
• This decrease in receptor availability likely contributes to the altered action of 1,25-dihydroxyvitamin D3 on bone in magnesium-deficient states.
• Findings may explain clinical observations in hypoparathyroid patients with magnesium deficiency.